Benitec Biopharma Inc. BNTC
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -20.12% | -22.79% | -86.82% | -100.53% | -74.32% |
| Total Depreciation and Amortization | 21.46% | 28.73% | 30.88% | 20.17% | 15.45% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 58.50% | 138.58% | 664.46% | 1,721.87% | 1,905.05% |
| Change in Net Operating Assets | 178.31% | -231.60% | 38.81% | -2,743.37% | -332.45% |
| Cash from Operations | 29.97% | -6.02% | 15.28% | -15.15% | -21.57% |
| Capital Expenditure | -483.33% | -44.44% | 91.10% | 89.94% | 89.94% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -483.33% | -44.44% | 91.10% | 89.94% | 89.94% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 44.56% | -4.61% | 66.86% | -20.99% | -1.56% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -170.20% | -21.56% | -192.90% | 20.80% | 60.64% |
| Cash from Financing | 40.42% | -5.87% | 62.30% | -20.95% | 3.61% |
| Foreign Exchange rate Adjustments | -355.10% | -242.07% | -162.33% | 255.41% | 712.50% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 75.22% | -8.80% | 90.76% | -36.50% | -3.12% |